Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

280.40USD
18 May 2018
Change (% chg)

$-0.17 (-0.06%)
Prev Close
$280.57
Open
$281.01
Day's High
$282.65
Day's Low
$280.07
Volume
613,514
Avg. Vol
652,331
52-wk High
$370.53
52-wk Low
$244.31

Latest Key Developments (Source: Significant Developments)

Biogen Reports Quarterly Revenues Of $3.1 Billion
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Biogen Inc ::BIOGEN REPORTS QUARTERLY REVENUES OF $3.1 BILLION.Q1 REVENUE $3.1 BILLION VERSUS I/B/E/S VIEW $3.16 BILLION.QTRLY NON-GAAP DILUTED EPS $6.05.QTRLY EARNINGS PER SHARE $5.54.QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR.QTRLY PLEGRIDY REVENUE OF $100 MILLION VERSUS. $112 MILLION REPORTED LAST YEAR.QTRLY TYSABRI REVENUE OF $$462 MILLION VERSUS. $545 MILLION REPORTED LAST YEAR.QTRLY TECFIDERA REVENUE OF $987 MILLION VERSUS $958 MILLION REPORTED LAST YEAR.QTRLY AVONEX REVENUE OF $451 MILLION VERSUS $537 MILLION REPORTED LAST YEAR.Q1 EARNINGS PER SHARE VIEW $5.94 -- THOMSON REUTERS I/B/E/S.  Full Article

Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar
Thursday, 5 Apr 2018 

April 5 (Reuters) - Biogen Inc ::BIOGEN AND SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE ALLOWING COMMERCIALIZATION OF IMRALDI™ (ADALIMUMAB BIOSIMILAR) IN EUROPE.BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018.PRECISE TERMS OF AGREEMENT WITH ABBVIE ARE CONFIDENTIAL.UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE.COUNTRY BASIS.UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE.COMPANIES HAVE AGREED TO DISMISS ALL PENDING PATENT LITIGATION.  Full Article

Biogen Inc Reports Qtrly Loss Per Share Of $1.40
Thursday, 25 Jan 2018 

Jan 25 (Reuters) - Biogen Inc ::BIOGEN REPORTS RECORD REVENUES FOR BOTH THE FULL YEAR AND FOURTH QUARTER OF 2017, $12.3 BILLION AND $3.3 BILLION, RESPECTIVELY.2018 FULL YEAR REVENUE GUIDANCE OF $12.7 TO $13.0 BILLION.2017 GAAP EPS DECREASED 30%, INCLUDING A $1.2 BILLION CHARGE DUE TO U.S. TAX REFORM.QTRLY ‍NON-GAAP DILUTED EPS $5.26​.QTRLY LOSS PER SHARE $1.40.QTRLY PLEGRIDY REVENUE OF $125​ MILLION VERSUS. $125 MILLION.QTRLY TYSABRI REVENUE OF $463​ MILLION VERSUS. $474 MILLION.GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $22.20 AND $23.20 FOR 2018.QTRLY TECFIDERA REVENUE OF $1,076 MILLION VERSUS. $1,002 MILLION.NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.20 AND $25.20 FOR 2018.QTRLY AVONEX REVENUE OF $520 MILLION VERSUS. $564 MILLION.FY2018 EARNINGS PER SHARE VIEW $24.16, REVENUE VIEW $12.68 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $5.45, REVENUE VIEW $3.08 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUES $3,307 MILLION VERSUS $2,872 MILLION LAST YEAR.‍IN Q4 CO BOOKED A GAAP & NON-GAAP TAX CHARGE OF $42 MILLION & $50 MILLION, RESPECTIVELY, RELATED TO IMPAIRMENT OF ZINBRYTA RELATED TAX ASSETS​.  Full Article

Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA).BIOGEN - CDEC'S RECOMMENDATION DISAPPOINTS AS CLINICAL CRITERIA, CONDITIONS LIMIT PATIENTS WITH SMA THAT COULD POTENTIALLY BENEFIT FROM SPINRAZA.  Full Article

Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Biogen Inc ::BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY.BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION.‍IONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.BIOGEN WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND COMMERCIALIZATION.ON COMMERCIALIZATION OF NOVEL THERAPIES TO TREAT SPINAL MUSCULAR ATROPHY​, BIOGEN TO PAY IONIS PERFORMANCE MILESTONES, ROYALTIES ON NET SALES.  Full Article

Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Biogen Inc ::SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING.  Full Article

Biogen appoints Jeff Capello as executive vice president and chief financial officer
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Biogen Inc ::Appoints Jeff Capello as executive vice president and chief financial officer.Says Capello's appointment as CFO effective as of Dec 11, 2017​.  Full Article

Acorda announces royalty monetization transactions for $53 mln
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Acorda Therapeutics Inc :Acorda announces royalty monetization transactions for $53 million.Acorda Therapeutics - A $40 million royalty monetization with healthcare royalty partners and a $13 million royalty monetization with H. Lundbeck A/S​.Acorda Therapeutics Inc - ‍ In return for payment to Acorda, HCR obtains right to receive royalty revenue on Fampyra payable by Biogen.Acorda - ‍H. Lundbeck, Acorda amended license agreement for selincro to eliminate future royalty, milestone obligations on sale of Selincro outside U.S..Acorda Therapeutics Inc - Transaction does not include potential future milestones to be paid by Biogen​.  Full Article

Biogen presents new data from long-term extension of phase 1B study
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global collaboration agreement to jointly develop and commercialize aducanumab​.Biogen Inc - ‍results are consistent with previously reported analyses from phase 1B study​.  Full Article

Biogen Q3 earnings per share $5.79
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Biogen Inc ::Biogen reports quarterly revenues of $3.1 billion.Q3 revenue $3.1 billion versus I/B/E/S view $3.04 billion.Biogen Inc - ‍company restructures collaboration arrangements with eisai and neurimmune to improve long-term value of aducanumab​.Biogen qtrly ‍ non-gaap diluted eps $ 6.31​.Q3 earnings per share $5.79.Biogen - qtrly tecfidera revenue of ‍$ 1,070​ million versus. $1,034 million.Biogen - qtrly plegridy revenue of $‍​124 million versus $128 million last year.Biogen - qtrly avonex revenue of $‍538​ million versus. $580 million.Biogen - qtrly tysabri revenue of $‍​469 million versus $515 million last year.Biogen - qtrly spinraza revenue of $‍271​ million versus. $203 million in q2.Q3 earnings per share view $5.73 -- Thomson Reuters I/B/E/S.  Full Article

UPDATE 2-S.Korea's Samsung BioLogics says partner to boost stake in JV at heart of probe

* Move eases uncertainty over accounting probe - analyst (Add share prices, background on stake)